The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Selective serotonin reuptake inhibitors for premenstrual syndrome
Open accessAbstract
BACKGROUND: Premenstrual syndrome (PMS) is a common cause of physical, psychological and social problems in women of reproductive age. The key characteristic of PMS is the timing of symptoms, which occur only during the two weeks leading up to menstruation (the luteal phase of the menstrual cycle). Selective serotonin reuptake inhibitors (SSRIs) are increasingly used as first line therapy for PMS. SSRIs can be taken either in the luteal phase or else continuously (every day). SSRIs are generally considered to be effective for reducing premenstrual symptoms but they can cause adverse effects. OBJECTIVES: The objective of this review was to evaluate the effectiveness and safety of SSRIs for treating premenstrual syndrome. SEARCH METHODS: Electronic searches for relevant randomised controlled trials (RCTs) were undertaken in the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, PsycINFO, and CINAHL (February 2013). Where insufficient data were presented in a report, attempts were made to contact the original authors for further details. SELECTION CRITERIA: Studies were considered in which women with a prospective diagnosis of PMS, PMDD or late luteal phase dysphoric disorder (LPDD) were randomised to receive SSRIs or placebo for the treatment of premenstrual syndrome. DATA COLLECTION AND ANALYSIS: Two review authors independently selected the studies, assessed eligible studies for risk of bias, and extracted data on premenstrual symptoms and adverse effects. Studies were pooled using random-effects models. Standardised mean differences (SMDs) with 95% confidence intervals (CIs) were calculated for premenstrual symptom scores, using separate analyses for different types of continuous data (that is end scores and change scores). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Analyses were stratified by type of drug administration (luteal or continuous) and by drug dose (low, medium, or high). We calculated the number of women who would need to be taking a moderate dose of SSRI in order to cause one additional adverse event (number needed to harm: NNH). The overall quality of the evidence for the main findings was assessed using the GRADE working group methods. MAIN RESULTS: Thirty-one RCTs were included in the review. They compared fluoxetine, paroxetine, sertraline, escitalopram and citalopram versus placebo. SSRIs reduced overall self-rated symptoms significantly more effectively than placebo. The effect size was moderate when studies reporting end scores were pooled (for moderate dose SSRIs: SMD -0.65, 95% CI -0.46 to -0.84, nine studies, 1276 women; moderate heterogeneity (I(2) = 58%), low quality evidence). The effect size was small when studies reporting change scores were pooled (for moderate dose SSRIs: SMD -0.36, 95% CI -0.20 to -0.51, four studies, 657 women; low heterogeneity (I(2)=29%), moderate quality evidence).SSRIs were effective for symptom relief whether taken only in the luteal phase or continuously, with no clear evidence of a difference in effectiveness between these modes of administration. However, few studies directly compared luteal and continuous regimens and more evidence is needed on this question.Withdrawals due to adverse effects were significantly more likely to occur in the SSRI group (moderate dose: OR 2.55, 95% CI 1.84 to 3.53, 15 studies, 2447 women; no heterogeneity (I(2) = 0%), moderate quality evidence). The most common side effects associated with a moderate dose of SSRIs were nausea (NNH = 7), asthenia or decreased energy (NNH = 9), somnolence (NNH = 13), fatigue (NNH = 14), decreased libido (NNH = 14) and sweating (NNH = 14). In secondary analyses, SSRIs were effective for treating specific types of symptoms (that is psychological, physical and functional symptoms, and irritability). Adverse effects were dose-related.The overall quality of the evidence was low to moderate, the main weakness in the included studies being poor reporting of methods. Heterogeneity was low or absent for most outcomes, though (as noted above) there was moderate heterogeneity for one of the primary analyses. AUTHORS' CONCLUSIONS: SSRIs are effective in reducing the symptoms of PMS, whether taken in the luteal phase only or continuously. Adverse effects are relatively frequent, the most common being nausea and asthenia. Adverse effects are dose-dependent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Vitex agnus castus for premenstrual syndrome
Shaw, S., Wyatt, K. M., Campbell, J., Ernst, E., & Coon, J. T. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004632 · Cited by 3
Self-citationRetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Fluoxetine in the Treatment of Premenstrual Dysphoria
Steiner, M., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., Grover, D., & Streiner, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322301 · Cited by 445
Progesterone metabolite allopregnanolone in women with premenstrual syndrome
RAPKIN, A., MORGAN, M., GOLDMAN, L., BRANN, D., SIMONE, D., & MAHESH, V (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00417-1 · Cited by 376
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review
Dimmock, P. W., Wyatt, K. M., Jones, P. W., & O'Brien, P. S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02754-9 · Cited by 368
Self-citationPremenstrual dysphoric disorder: Evidence for a new category for DSM-5
Epperson, C. N., Steiner, M., Hartlage, S. A., Eriksson, E., Schmidt, P. J., Jones, I., & Yonkers, K. A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11081302 · Cited by 361
Dettori, J. (2011) · Evidence-Based Spine-Care Journal · doi:10.1055/s-0030-1267080 · Cited by 336
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Greene, R., & Dalton, K. (1953) · BMJ · doi:10.1136/bmj.1.4818.1007 · Cited by 314
O’Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E., Halbreich, U., Ismail, K. M. K., et al. (2011) · Archives of Women's Mental Health · doi:10.1007/s00737-010-0201-3 · Cited by 295
Self-citationOral contraceptives containing drospirenone for premenstrual syndrome
Lopez, L. M., Kaptein, A. A., & Helmerhorst, F. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006586.pub4 · Cited by 270
Premenstrual syndromes: overview from a methodologic perspective
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.2.163 · Cited by 223
Eriksson, E. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00076-c · Cited by 212
Whole-blood serotonin in premenstrual syndrome.
Rapkin, A. J., Edelmuth, E., Chang, L., Reading, A. E., McGuire, M. T., & Su, T. (1987) · PubMed · Cited by 188
Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.10.932 · Cited by 176
Yonkers, K. A. (1997) · JAMA · doi:10.1001/jama.278.12.983 · Cited by 165
Wikander, I., Sundblad, C., Andersch, B., Dagnell, I., Zylberstein, D., Bengtsson, F., & Eriksson, E. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199810000-00007 · Cited by 164
Sexual dysfunction during antidepressant treatment
(1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)91203-4 · Cited by 163
Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo‐controlled trial
Sundblad, C., Modigh, K., Andersch, B., & Eriksson, E. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb01440.x · Cited by 161
Sundblad, C., Hedberg, M. A., & Eriksson, E. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.52 · Cited by 158
Pearlstein, T. B., Halbreich, U. M., Batzar, E. D., Brown, C., Endicott, J., Frank, E., Freeman, E. W., Harrison, W. M., Haskett, R. F., Stout, A. L., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0205 · Cited by 156
Wood, S. H., Mortola, J. F., Chan, Y., Moossazadeh, F., & Yen, S. S. C. (1992) · PubMed · Cited by 155
Pretreatment pattern of symptom expression in premenstrual dysphoric disorder
Pearlstein, T. B., Yonkers, K. A., Fayyad, R. S., & Gillespie, J. A. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.10.004 · Cited by 150
Comparison of Fluoxetine, Bupropion, and Placebo in the Treatment of Premenstrual Dysphoric Disorder
Pearlstein, T. B., Stone, A. B., Lund, S. A., Scheft, H., Zlotnick, C., & Brown, W. A. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00004 · Cited by 142
Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder
Pearlstein, T. B., Frank, E., Rivera-Tovar, A., Thoft, J. S., Jacobs, E. A., & Mieczkowski, T. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90126-s · Cited by 141
Treatment of Premenstrual Dysphoric Disorder With Sertraline During the Luteal Phase
Young, S. A., Hurt, P. H., Benedek, D. M., & Howard, R. S. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0206 · Cited by 136
Cohen, L. S. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02166-x · Cited by 133
Fluoxetine in the treatment of late luteal phase dysphoric disorder.
Stone, A. B., Pearlstein, T. B., & Brown, W. A. (1991) · PubMed · Cited by 132
Serotonin Levels and Platelet Uptake during Premenstrual Tension
Taylor, D. L., Mathew, R. J., Ho, B. T., & Weinman, M. L. (2008) · Neuropsychobiology · doi:10.1159/000118103 · Cited by 131
Shah, N., Jones, J. B., Aperi, J., Shemtov, R., Karne, A., & Borenstein, J. (2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31816fd73b · Cited by 130
Efficacy of Intermittent, Luteal Phase Sertraline Treatment of Premenstrual Dysphoric Disorder
Halbreich, U. M., Bergeron, R., Yonkers, K. A., Freeman, E., Stout, A. L., & Cohen, L. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02326-8 · Cited by 125
Bancroft, J., Cook, A., Davidson, D., Bennie, J., & Goodwin, G. M. (1991) · Psychological Medicine · doi:10.1017/s0033291700020407 · Cited by 124
Ashby, C. R., Carr, L. A., Cook, C. L., Steptoe, M. M., & Franks, D. D. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90277-6 · Cited by 122
Intermittent Luteal Phase Sertraline Treatment of Dysphoric Premenstrual Syndrome
Halbreich, U. M., & Smoller, J. W. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0905 · Cited by 116
Jermain, D. M. (1999) · Archives of Family Medicine · doi:10.1001/archfami.8.4.328 · Cited by 114
Kinetics of citalopram in man; plasma levels in patients
Overø, K. F. (1982) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(82)80181-4 · Cited by 113
Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria.
Steiner, M. S., Korzekwa, M., Lamont, J. A., & Wilkins, A. (1997) · PubMed · Cited by 111
Fluoxetine in the Treatment of Premenstrual Dysphoria
Su, T., Schmidt, P. J., Danaceau, M. A., Tobin, M. B., Rosenstein, D. L., Murphy, D. L., & Rubinow, D. R. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00245-x · Cited by 98
Fluoxetine treatment of severe premenstrual syndrome.
Menkes, D. B., Taghavi, E., Mason, P. A., Spears, G. F. S., & Howard, R. (1992) · BMJ · doi:10.1136/bmj.305.6849.346 · Cited by 98
Landén, M., Nissbrandt, H., Allgulander, C., Sörvik, K., Ysander, C., & Eriksson, E. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301216 · Cited by 96
Miner, C. M., Brown, E., McCray, S., Gonzales, J. S., & Wohlreich, M. M. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85043-3 · Cited by 95
Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes
Ladisich, W. (1977) · Psychoneuroendocrinology · doi:10.1016/0306-4530(77)90042-7 · Cited by 95
Kleinstäuber, M., Witthöft, M., & Hiller, W. (2012) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-012-9299-y · Cited by 94
BUSPIRONE IN TREATMENT OF PREMENSTRUAL SYNDROME
Rickels, K., Freeman, E. W., & Sondheimer, S. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92591-9 · Cited by 93
Fluoxetine in the treatment of premenstrual syndrome
Özeren, S., Çorakçı, A., Yücesoy, İ., Mercan, R., & Erhan, G. (1997) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(97)02741-3 · Cited by 91
Freeman, E. W., Rickels, K., Sondheimer, S. J., Polansky, M., & Xiao, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.343 · Cited by 91
Dennerstein, L., Gotts, G. H., Brown, J. B., Morse, C. A., Farley, T. M. M., & Pinol, A. (1994) · Psychoneuroendocrinology · doi:10.1016/0306-4530(94)90067-1 · Cited by 89
Self-citationLong-term fluoxetine treatment of late luteal phase dysphoric disorder.
Pearlstein, T. B., & Stone, A. B. (1994) · PubMed · Cited by 87
Imipramine Receptor Binding and Serotonin Uptake in Platelets of Women with Premenstrual Changes
Rojansky, N., Halbreich, U. M., Zander, K., Barkai, A. I., & Goldstein, S. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000293135 · Cited by 86
Shen, W. W., & Hsu, J. H. (1995) · The International Journal of Psychiatry in Medicine · doi:10.2190/n6c0-dwx2-g4ea-7688 · Cited by 83
Halbreich, U. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900016849 · Cited by 79
Characteristics of Women Seeking Treatment for Premenstrual Syndrome
Harrison, W. M., Endicott, J., Nee, J. C. M., Glick, H., & Rabkin, J. G. (1989) · Psychosomatics · doi:10.1016/s0033-3182(89)72246-5 · Cited by 77
Full- or Half-Cycle Treatment of Severe Premenstrual Syndrome With a Serotonergic Antidepressant
Freeman, E. W., Rickels, K., Arredondo, F., Kao, L.-C., Pollack, S. E., & Sondheimer, S. J. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00002 · Cited by 75
COHEN, I. R., & WISE, P. M. (1988) · Endocrinology · doi:10.1210/endo-122-6-2619 · Cited by 73
Progesterone for premenstrual syndrome
Ford, O., Lethaby, A. E., Roberts, H., & Mol, B. W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003415.pub3 · Cited by 73
Cohen, L. S., Soares, C. N., Yonkers, K. A., Bellew, K. M., Bridges, I. M., & Steiner, M. S. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000140005.94790.9c · Cited by 73
Helping women with premenstrual syndrome.
O’Brien, P. M. S. (1993) · BMJ · doi:10.1136/bmj.307.6917.1471 · Cited by 72
Self-citationBoth-Orthman, B., Rubinow, D. R., Hoban, M. C., Malley, J. D., & Grover, G. N. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.628 · Cited by 70
Paroxetine as a Treatment for Premenstrual Dysphoric Disorder
Yonkers, K. A., Gullion, C. M., Williams, A., Novak, K. J., & Rush, A. J. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00002 · Cited by 70
Progesterone for premenstrual syndrome
Ford, O., Lethaby, A. E., Roberts, H., & Mol, B. W. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003415.pub4 · Cited by 69
Low-Dose Sertraline in the Treatment of Moderate-to-Severe Premenstrual Syndrome
Kornstein, S. G., Pearlstein, T. B., Fayyad, R. S., Farfel, G. M., & Gillespie, J. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1020 · Cited by 68
Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder
Steiner, M. S., Brown, E., Trzepacz, P. T., Dillon, J., Berger, C., Carter, D., Reid, R. L., & Stewart, D. E. (2003) · Archives of Women s Mental Health · doi:10.1007/s00737-002-0162-2 · Cited by 68
Steiner, M. S., Hirschberg, A. L., Bergeron, R., Holland, F., Gee, M., & van Erp, E. J. M. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.01.021 · Cited by 67
Steiner, M. S., Romano, S. J., Babcock, S. W., Dillon, J., Shuler, C., Berger, C., Carter, D., Reid, R. L., Stewart, D. E., Steinberg, S. I., et al. (2001) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2001.00120.x · Cited by 66
Fluoxetineʼs spectrum of action in premenstrual syndrome
Menkes, D. B., Taghavi, E., Mason, P. A., & Howard, R. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300820-00003 · Cited by 65
A double-blind trial of four medications to treat severe premenstrual syndrome
Diêgoli, M. S. C., da Fonseca, Â. M., Diêgoli, C. A., & Pinotti, J. A. (1998) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(98)00035-6 · Cited by 63
A naturalistic study of paroxetine in premenstrual syndrome:
Sundblad, C., Wikander, I., Andersch, B., & Eriksson, E. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00404-5 · Cited by 62
Eriksson, E., Ekman, A., Sinclair, S., Sörvik, K., Ysander, C., Mattson, U.-B., & Nissbrandt, H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181678a28 · Cited by 57
Fluoxetine in the treatment of premenstrual syndrome.
Ab, S., Pearlstein, T. B., & Wa, B. (1990) · PubMed · Cited by 54
Pearlstein, T. (2002) · Drugs · doi:10.2165/00003495-200262130-00004 · Cited by 53
Freeman, E. W., Sondheimer, S. J., Sammel, M. D., Ferdousi, T., & Lin, H. Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0616 · Cited by 53
Landén, M., Erlandsson, H., Bengtsson, F., Andersch, B., & Eriksson, E. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.86 · Cited by 52
Time to Relapse After Short- or Long-term Treatment of Severe Premenstrual Syndrome With Sertraline
Freeman, E. W., Rickels, K., Sammel, M. D., Lin, H., & Sondheimer, S. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.547 · Cited by 51
Symptom-Onset Treatment for Women with Premenstrual Dysphoric Disorder
Yonkers, K. A., Holthausen, G. A., Poschman, K., & Howell, H. B. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203197.03829.ae · Cited by 48
Fluvoxamine in the treatment of menstrually related mood disorders
Veeninga, A. T., Westenberg, H. G. M., & Weusten, J. T. N. (1990) · Psychopharmacology · doi:10.1007/bf02244113 · Cited by 47
Chinese herbal medicine for premenstrual syndrome
Jing, Z., Yang, X., ISMAIL, K. M. K., Chen, X. Y., & Wu, T. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006414.pub2 · Cited by 46
Sertraline in the treatment of premenstrual dysphoric disorder.
Yonkers, K. A., Halbreich, U. M., Freeman, E. W., Brown, C., & Pearlstein, T. B. (1996) · PubMed · Cited by 46
Naheed, B., Kuiper, J. H., Uthman, O. A., O’Mahony, F., & O’Brien, P. M. S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010503.pub2 · Cited by 44
Self-citationClinical Subtypes of Premenstrual Syndrome and Responses to Sertraline Treatment
Freeman, E. W., Sammel, M. D., Lin, H., Rickels, K., & Sondheimer, S. J. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e318236edf2 · Cited by 42
Open Trial of Fluoxetine Therapy for Premenstrual Syndrome
Elks, M. L. (1993) · Southern Medical Journal · doi:10.1097/00007611-199305000-00003 · Cited by 41
Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial.
Ew, F., Rickels, K., Sondheimer, S. J., & Wittmaack, F. M. (1996) · PubMed · Cited by 41
The pharmacologic management of premenstrual dysphoric disorder
Rapkin, A. J., & Winer, S. A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.3.429 · Cited by 38
Premenstrual syndrome (PMS): A peri-menopausal perspective
Baker, L. J., & O’Brien, P. M. S. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.03.007 · Cited by 36
Self-citationYonkers, K. A., Pearlstein, T. B., Fayyad, R. S., & Gillespie, J. A. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.10.006 · Cited by 35
Pearlstein, T. B., Bellew, K. M., Endicott, J., & Steiner, M. S. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0203 · Cited by 35
Luteal Phase Administration of Paroxetine for the Treatment of Premenstrual Dysphoric Disorder
Steiner, M. S., Ravindran, A. V., Mellédo, J. L., Carter, D., Huang, J. O., Anonychuk, A. M., & Simpson, S. D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0616 · Cited by 34
Citalopram in PMS Patients with Prior SSRI Treatment Failure: A Preliminary Study
Freeman, E. W., Jabara, S. I., Sondheimer, S. J., & Auletto, R. (2002) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/15246090260137635 · Cited by 32
Serotonin and gender-specific psychiatric disorders
Steiner, M. S., Lepage, P., & Dunn, E. J. (1997) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651509709069200 · Cited by 30
Pearlstein, T. B., Joliat, M. J., Brown, E. B., & Miner, C. M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.207 · Cited by 26
Wu, K., LIU, C., & Hsiao, M. (2008) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2007.01785.x · Cited by 23
Predictors of Response to Sertraline Treatment of Severe Premenstrual Syndromes
Freeman, E. W., Sondheimer, S. J., Polansky, M., & Garcia-Espagn, B. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0807 · Cited by 22
Treatment of premenstrual syndrome with fluoxetine
Brandenburg, S., Tuynman-Qua, H. G., Verheij, R., & Pepplinkhuizen, L. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300840-00018 · Cited by 20
Alpay, F. B., & Turhan, N. Ö. (2001) · PubMed · Cited by 19
Platelet monoamine oxidase B activity in women with premenstrual syndrome
Rapkin, A. J., Buckman, T. D., Sutphin, M. S., et al. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(88)90590-x · Cited by 15
Public disclosure of clinical research
Strahlman, E. R., Rockhold, F. W., & Freeman, A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60613-9 · Cited by 12
Vitex agnus castus for premenstrual syndrome
Shaw, S., Wyatt, K. M., Campbell, J., Ernst, E., & Coon, J. T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004632.pub2 · Cited by 12
Self-citation[Premenstrual dysphoric disorder: long-term treatment with fluoxetine and discontinuation].
Martín, J. J. D. L. G. (1997) · PubMed · Cited by 10
Ramos, M. F., Uribe, M. O., & Sotres, J. C. (2003) · Salud Mental · Cited by 6
Predictors of response to luteal phase fluoxetine treatment of PMDD
Cohen, L., Davis, S., O’Brien, P. M. S., Brown, E., Miner, C., & Jacobson, J. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80134-1 · Cited by 4
Self-citation
Cited by
Management of functional somatic syndromes
Henningsen, P., Zipfel, S., & Herzog, W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60159-7 · Cited by 741
Yonkers, K. A., O'Brien, P. S., & Eriksson, E. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60527-9 · Cited by 541
Self-citationSelective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Management of functional somatic syndromes and bodily distress
Henningsen, P., Zipfel, S., Sattel, H., & Creed, F. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000484413 · Cited by 335
Premenstrual Dysphoric Disorder: Epidemiology and Treatment
Hantsoo, L., & Epperson, C. N. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0628-3 · Cited by 329
Metadata
- Authors
- Marjoribanks, J., Brown, J., O'Brien, P. M. S., & Wyatt, K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-06-07
- Issue
- 6
- Pages
- CD001396-CD001396
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2116594963
- Cited by
- 413
- References
- 104
- FWCI
- 28.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.